passages: 741
passages: document
passages: Reduced platelet thromboxane formation after long-term administration of a dihydropyridine calcium channel blocker : a prospective , double-blind , placebo-controlled study with nitrendipine in borderline hypertensive patients with IDDM-type diabetes mellitus . Twenty-nine IDDM patients with borderline hypertension were randomly allocated to placebo or nitrendipine treatment . Nitrendipine was given orally at a dosage of 20 mg once daily over 4 weeks . Stimulated platelet thromboxane formation at rest and after standardized , non exhausting exercise was measured by standard methods . In addition , plasma levels of platelet factor 4 and aggregation responses to collagen and ADP were determined . In the treatment group thromboxane formation after stimulation with collagen ( 0.3 and 1.0 micrograms/ml ) and 1 mM arachidonic acid ( AA ) was reduced in the resting state . Exercise induced change of thromboxane synthesis in response to 1.0 micrograms/ml collagen was significantly lower as compared to placebo ( p < 0.05 ) . In parallel , PF4 plasma levels were significantly lowered ( p < 0.05 ) . Whole blood aggregation after collagen stimulation ( 1.0 micrograms/ml ) was reduced after 4 weeks of nitrendipine treatment , but ADP ( 5 microM ) induced aggregation was not . These effects of nitrendipine were not seen in platelet rich plasma . In conclusion long-term nitrendipine treatment may inhibit collagen dependent platelet activation in the blood of diabetic patients with borderline hypertension .
entities: 742
entities: Intervention_Pharmacological
entities: dihydropyridine calcium channel blocker
entities: 743
entities: Intervention_Pharmacological
entities: nitrendipine
entities: 744
entities: Intervention_Control
entities: placebo
entities: 745
entities: Intervention_Pharmacological
entities: nitrendipine
entities: 746
entities: Intervention_Pharmacological
entities: Nitrendipine
entities: 747
entities: Intervention_Control
entities: placebo
entities: 748
entities: Intervention_Pharmacological
entities: nitrendipine
entities: 749
entities: Intervention_Pharmacological
entities: nitrendipine
entities: 750
entities: Intervention_Pharmacological
entities: nitrendipine
entities: 751
entities: Outcome_Physical
entities: platelet thromboxane formation
entities: 752
entities: Outcome_Physical
entities: Stimulated platelet thromboxane formation
entities: 753
entities: Outcome_Physical
entities: plasma levels of platelet factor 4 and aggregation responses to collagen and ADP
entities: 754
entities: Outcome_Physical
entities: thromboxane formation
entities: 755
entities: Outcome_Physical
entities: Exercise induced change of thromboxane synthesis
entities: 756
entities: Outcome_Physical
entities: PF4 plasma levels
entities: 757
entities: Outcome_Physical
entities: Whole blood aggregation after collagen stimulation
entities: 758
entities: Outcome_Physical
entities: aggregation
entities: 759
entities: Outcome_Physical
entities: collagen dependent platelet activation
entities: 760
entities: Participant_Condition
entities: borderline hypertensive patients with IDDM-type diabetes mellitus .
entities: 761
entities: Participant_Sample-size
entities: Twenty-nine
entities: 762
entities: Participant_Condition
entities: IDDM patients with borderline hypertension
entities: 763
entities: Participant_Condition
entities: diabetic patients with borderline hypertension .